Autocrine NGFbeta/TRKA signalling is an important survival factor for Hodgkin lymphoma derived cell lines.
Standard
Autocrine NGFbeta/TRKA signalling is an important survival factor for Hodgkin lymphoma derived cell lines. / Renné, Christoph; Minner, Sarah Jane Pauline; Küppers, Ralf; Hansmann, Martin-Leo; Bräuninger, Andreas.
In: LEUKEMIA RES, Vol. 32, No. 1, 1, 2008, p. 163-167.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Autocrine NGFbeta/TRKA signalling is an important survival factor for Hodgkin lymphoma derived cell lines.
AU - Renné, Christoph
AU - Minner, Sarah Jane Pauline
AU - Küppers, Ralf
AU - Hansmann, Martin-Leo
AU - Bräuninger, Andreas
PY - 2008
Y1 - 2008
N2 - Hodgkin-Reed/Sternberg cells, the tumor cells of Hodgkin lymphoma, aberrantly express several receptor tyrosine kinases, among them TRKA whose stimulation supports B cell survival. We show here high expression of TRKA in Hodgkin-Reed/Sternberg cell lines as compared to normal B cells and other B cell lymphomas, without major increases in TRKA gene dosage. A fraction of TRKA is constitutively activated, likely due to the coexpression of NGFbeta, the TRKA high affinity ligand. The TRK inhibitor K-252a decreased survival of Hodgkin-Reed/Sternberg cell lines accompanied by decreased AKT activation. Inclusion of TRK inhibitors in therapeutic regimens may thus be an interesting possibility.
AB - Hodgkin-Reed/Sternberg cells, the tumor cells of Hodgkin lymphoma, aberrantly express several receptor tyrosine kinases, among them TRKA whose stimulation supports B cell survival. We show here high expression of TRKA in Hodgkin-Reed/Sternberg cell lines as compared to normal B cells and other B cell lymphomas, without major increases in TRKA gene dosage. A fraction of TRKA is constitutively activated, likely due to the coexpression of NGFbeta, the TRKA high affinity ligand. The TRK inhibitor K-252a decreased survival of Hodgkin-Reed/Sternberg cell lines accompanied by decreased AKT activation. Inclusion of TRK inhibitors in therapeutic regimens may thus be an interesting possibility.
M3 - SCORING: Zeitschriftenaufsatz
VL - 32
SP - 163
EP - 167
JO - LEUKEMIA RES
JF - LEUKEMIA RES
SN - 0145-2126
IS - 1
M1 - 1
ER -
